BELVIQ/BELVIQ XR has not been studied in patients Post-Marketing Experience. 7 .. short- term studies [see Adverse Reactions (), Drug Abuse and. Official Title: Belviq Tablet® Post Marketing Surveillance Protocol. Actual Study Start Date: February 2, Estimated Primary Completion. Belviq (lorcaserin) is no wonder drug, but it can help people to lose about The firm has agreed to run six post-marketing studies, including a.

Belviq (lorcaserin) is no wonder drug, but it can help people to lose about The firm has agreed to run six post-marketing studies, including a. OUTCOMES TRIAL OF ANTI-OBESITY AGENT BELVIQ® is posted. in the U.S.: BELVIQ®, “BELVIQ”) in 12, patients as a post-marketing clinical trial . III clinical studies on lorcaserin were headache, dizziness, fatigue. 1 Garrison, N. Label and Labeling Review for Belviq XR (NDA ). . from DMEP on the post-marketing surveillance of lorcaserin (IR). BELVIQ/BELVIQ XR has not been studied in patients Post-Marketing Experience. 7 .. short- term studies [see Adverse Reactions (), Drug Abuse and. However, many of these medications have been withdrawn from the market . Patients were instructed to return to their research site 2 and 4 weeks after. Belviq (lorcaserin) received FDA approval July 26 [9]. Belviq was approved without a REMS, but six postmarketing studies were required, including a. This study will be conducted to demonstrate weight loss efficacy by change in body mass index (BMI) and safety in adolescents age 12 to Official Title: Belviq Tablet® Post Marketing Surveillance Protocol. Actual Study Start Date: February 2, Estimated Primary Completion. BELVIQ/BELVIQ XR has not been studied in Post-Marketing Experience .. hypoglycemia after starting BELVIQ/BELVIQ XR, appropriate changes should.